CytomX Therapeutics (NASDAQ:CTMX) Given “Neutral” Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a report issued on Monday morning,Benzinga reports. HC Wainwright also issued estimates for CytomX Therapeutics’ Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at $0.14 EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.12) EPS.

CytomX Therapeutics Price Performance

NASDAQ CTMX opened at $1.01 on Monday. The business has a 50 day moving average price of $1.13 and a 200 day moving average price of $1.46. The company has a market capitalization of $79.04 million, a P/E ratio of 6.03 and a beta of 1.06. CytomX Therapeutics has a 1-year low of $0.98 and a 1-year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The business had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. During the same quarter in the previous year, the company posted $0.04 EPS. On average, research analysts expect that CytomX Therapeutics will post -0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in CytomX Therapeutics in the 1st quarter valued at approximately $57,000. US Bancorp DE purchased a new stake in shares of CytomX Therapeutics in the third quarter valued at $40,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter valued at $124,000. XTX Topco Ltd increased its position in CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares in the last quarter. Finally, Forefront Analytics LLC raised its stake in CytomX Therapeutics by 206.7% in the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 43,176 shares during the last quarter. 67.77% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.